Potassium Chloride In Sodium Chloride

Sodium Chloride And Potassium Chloride


Icu Medical Inc.
Human Prescription Drug
NDC 0990-7116
Potassium Chloride In Sodium Chloride also known as Sodium Chloride And Potassium Chloride is a human prescription drug labeled by 'Icu Medical Inc.'. National Drug Code (NDC) number for Potassium Chloride In Sodium Chloride is 0990-7116. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Potassium Chloride In Sodium Chloride drug includes Potassium Chloride - 2.98 g/1000mL Sodium Chloride - 9 g/1000mL . The currest status of Potassium Chloride In Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 0990-7116
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Potassium Chloride In Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Chloride And Potassium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Icu Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:POTASSIUM CHLORIDE - 2.98 g/1000mL
SODIUM CHLORIDE - 9 g/1000mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Dec, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 28 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019686
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:ICU Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:237367
637551
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:660YQ98I10
451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
Potassium Compounds [CS]
Potassium Salt [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0990-7116-0912 POUCH in 1 CASE (0990-7116-09) / 1 BAG in 1 POUCH / 1000 mL in 1 BAG01 Dec, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Potassium chloride in sodium chloride sodium chloride and potassium chloride sodium chloride sodium cation potassium chloride potassium cation water potassium chloride in sodium chloride sodium chloride and potassium chloride sodium chloride sodium cation potassium chloride potassium cation water

Drug Interactions:

Drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (see precautions .)

Indications and Usage:

Indications and usage these solutions are indicated in patients requiring parenteral administration of potassium chloride and sodium chloride.

Warnings:

Warnings solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. to avoid potassium intoxication, do not infuse these solutions rapidly. in patients with severe renal insufficiency or adrenal insufficiency, administration of potassium chloride may cause potassium intoxication. solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. in patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. the intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk
of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. the risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

Dosage and Administration:

Dosage and administration these solutions should be administered only by intravenous infusion and as directed by the physician. the dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. if the serum potassium level is greater than 2.5 meq/liter, potassium should be given at a rate not to exceed 10 meq/hour in a concentration less than 30 meq/liter. somewhat faster rates and greater concentrations (usually up to 40 meq/liter) of potassium may be indicated in patients with more severe potassium deficiency. the total 24-hour dose should not generally exceed 200 meq of potassium. drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (see precautions .)

Contraindications:

Contraindications solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered.

Adverse Reactions:

Adverse reactions reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. the signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of p waves, spreading and slurring of the qrs complex with development of a biphasic curve and cardiac arrest. potassium-containing solutions are intrinsically i
rritating to tissues. therefore, extreme care should be taken to avoid perivascular infiltration. local tissue necrosis and subsequent sloughing may result if extravasation occurs. chemical phlebitis and venospasm have also been reported. should perivascular infiltration occur, i.v. administration at that site should be discontinued at once. local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, will often reduce venospasm and dilute the potassium remaining in the tissues locally. local application of heat may also be helpful.

Drug Interactions:

Drug interactions additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (see precautions .)

Use in Pregnancy:

Pregnancy category c: animal reproduction studies have not been conducted with potassium chloride or sodium chloride. it is also not known whether potassium chloride or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. potassium chloride or sodium chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use the safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. in neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

Overdosage:

Overdosage in the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels. (see warnings and precautions .)

Description:

Description intravenous solutions with potassium chloride (i.v. solutions with kcl) are sterile and nonpyrogenic solutions in water for injection. they are for administration by intravenous infusion only. see table for summary of content and characteristics of these solutions. the solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only for use as a single-dose injection. when smaller doses are required the unused portion should be discarded. these solutions are parenteral fluid and/or electrolyte replenishers. potassium chloride, usp is chemically designated kcl, a white granular powder freely soluble in water. sodium chloride, usp is chemically designated nacl, a white crystalline powder freely soluble in water. water for injection, usp is chemically designated h 2 0. the flexible plastic container is fabricated from a specially formulated polyvinylchloride. water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. solutions inside the plastic container also can leach out certain of its chemical components in very small amounts before the expiration period is attained. however, the safety of the plastic has been confirmed by tests in animals according to usp biological standards for plastic containers.

Clinical Pharmacology:

Clinical pharmacology when administered intravenously, these solutions provide a source of water and potassium chloride with 0.9% sodium chloride. intravenous solutions containing potassium chloride are particularly intended to provide needed potassium cation (k + ). potassium is the chief cation of body cells (160 meq/liter of intracellular water). it is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 meq/liter in a healthy adult). potassium plays an important role in electrolyte balance. normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. the kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. a deficiency of either potassium or chloride will lead to a deficit of the other. sodium chloride in water dissociates to provide sodium (na + ) and ch
loride (cl¯) ions. sodium (na + ) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. chloride (cl¯) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. the distribution and excretion of sodium (na + ) and chloride (cl¯) are largely under the control of the kidney which maintains a balance between intake and output. water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). water balance is maintained by various regulatory mechanisms. water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (na + ) plays a major role in maintaining physiologic equilibrium.

How Supplied:

How supplied intravenous solutions with potassium chloride (i.v. solution with kcl) are supplied in single-dose flexible plastic containers. see table: potassium chloride in 0.9% sodium chloride inj., usp composition approx. ionic concentrations (g/l) calculated (meq/l) ndc no. meq potassium size (ml) sodium chloride potassium chloride osmolarity (mosmol/l) ph (range) sodium (na + ) potassium (k + ) chloride (cl¯) approximate kcal/l 0409–7115–09 20 meq 1000 9 1.49 348 4.8 (3.5 to 6.5) 154 20 174 0 0990–7115–09 20 meq 1000 9 1.49 348 4.8 (3.5 to 6.5) 154 20 174 0 0409–7116–09 40 meq 1000 9 2.98 388 4.8 (3.5 to 6.5) 154 40 194 0 0990–7116–09 40 meq 1000 9 2.98 388 4.8 (3.5 to 6.5) 154 40 194 0 icu medical is transitioning ndc codes from the "0409" to a "0990" labeler code. both ndc codes are expected to be in the market for a period of time. store at 20 to 25°c (68 to 77°f). [see usp controlled room temperature.] protect from freezing. rev
ised: march, 2020 ifu0000168 icu medical, inc., lake forest, illinois, 60045, usa

Package Label Principal Display Panel:

Principal display panel - 20 meq bag label 20 meq potassium 1000 ml ndc 0990-7115-09 20 meq potassium chloride in 0.9% sodium chloride injection, usp each 100 ml contains potassium chloride 149 mg; sodium chloride 900 mg in water for injection. electrolytes per 1000 ml: potassium 20 meq; sodium 154 meq; chloride; 174 meq. 348 mosmol/liter (calc.) ph 4.8 (3.5 to 6.5) additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. single-dose container. for i.v. use. usual dosage: see insert. sterile, nonpyrogenic. use only if solution is clear and container is undamaged. must not be used in series connections. rx only 3 v contains dehp icu medical, inc., lake forest, illinois, 60045, usa icumedical imp0000049 principal display panel - 20 meq bag label

Principal display panel - 40 meq bag label 40 meq potassium 1000 ml ndc 0990-7116-09 40 meq potassium chloride in 0.9% sodium chloride injection, usp each 100 ml contains potassium chloride 298 mg; sodium chloride 900 mg in water for injection. electrolytes per 1000 ml: potassium 40 meq; chloride 194 meq; sodium 154 meq. 388 mosmol/liter (calc.) ph 4.8 (3.5 to 6.5) additives may be incompatible. consult with pharmacist, if available. when introducing additives, use aseptic technique, mix thoroughly and do not store. single-dose container. for i.v. use. usual dosage: see insert. sterile, nonpyrogenic. use only if solution is clear and container is undamaged. must not be used in series connections. rx only 3 v contains dehp imp0000050 icu medical, inc., lake forest, illinois, 60045, usa icumedical principal display panel - 40 meq bag label

Principal display panel - 1000 ml bag pouch to open tear at notch do not remove from overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see insert. 98-4321-r14-3/98 2 hdpe principal display panel - 1000 ml bag pouch


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.